CSII - Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates
- Cardiovascular Systems press release ( NASDAQ: CSII ): Q4 GAAP EPS of -$0.25 misses by $0.03 .
- Revenue of $62.5M (-12.0% Y/Y) misses by $0.46M .
- The Adjusted EBITDA loss increased to $4.3M from near breakeven in the prior year.
-
For the fiscal year ending June 30, 2023, CSI anticipates : Revenue of $255 million to $265 million vs. consensus of $261.3M, representing 8% to 12% growth compared to fiscal 22; Gross profit as a percentage of approximately 72% to 74% of revenues; Research and development expenses will be approximately 16% to 17% of revenues; Net loss in a range of 9% to 11% of revenues; and Adjusted EBITDA near break-even.
For further details see:
Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates